HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
NCT ID: NCT05902494
Last Updated: 2025-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
389 participants
OBSERVATIONAL
2023-06-29
2025-06-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will have urothelial cancer that has grown in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations
NCT03955913
HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598
NCT00896909
Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment
NCT02105168
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study
NCT03707574
Study of Human Epidermal Growth Receptor (HER2) Status Evaluation in Breast Cancer Pathology Samples
NCT02580799
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Locally advanced unresectable or metastatic stage disease
* Formalin fixed paraffin embedded (FFPE) tumor tissue blocks (or freshly sectioned slides, see laboratory manual for details) available for HER2 testing.
* At least 1 prior line of systemic therapy for locally advanced unresectable or metastatic urothelial carcinoma (LA/mUC), including 1 line of platinum-containing chemotherapy.
* Initiation of anticancer therapy for UC after prior progression on platinum-based therapy with or without maintenance avelumab between 01 January 2019 and 12 months before the end of data collection
* Radiographically documented and measurable disease progression immediately before index date
Exclusion Criteria
* Enrollment in a therapeutic clinical trial and received non-standard of care treatment during index line of therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seagen, a wholly owned subsidiary of Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic
Phoenix, Arizona, United States
University of California Irvine
Orange, California, United States
Stanford Cancer Institute - School of Medicine
Palo Alto, California, United States
University of California San Francisco
San Francisco, California, United States
University of California Los Angeles
Santa Monica, California, United States
University of Colorado Hospital
Aurora, Colorado, United States
ICAHN School of Medicine at Mount Sinai,
New York, New York, United States
Levine Cancer Institute
Charlotte, North Carolina, United States
Duke Cancer Institute - School of Medicine
Durham, North Carolina, United States
Avera Cancer Institute Center
Sioux Falls, South Dakota, United States
Vanderbilt - Ingram Cancer Center
Nashville, Tennessee, United States
AKH Wien
Vienna, , Austria
Chu Bordeaux Hopital Saint Andre
Bordeaux, , France
Centre Hospitalier Départemental Les Oudairies
La Roche-sur-Yon, , France
Centre Léon Bérard
Lyon, , France
Centre Antoine Lacassagne
Nice, , France
Institut Mutualiste Montsouris
Paris, , France
CHU LYON
Pierre-Bénite, , France
CHU de Rouen.
Rouen, , France
Foch Hospital
Suresnes, , France
Alexianer Krefeld GmbH
Krefeld, North Rhine-Westphalia, Germany
University Hospital Lübeck
Lübeck, Schleswig-Holstein, Germany
Stuttgart Hospital
Stuttgart, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C5731003
Identifier Type: OTHER
Identifier Source: secondary_id
SGNDV-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.